Method for treating ovarian cancer and/or Hodgkin lymphomia with a gold(III) complex

Patent metadata

Field	Value
Publication number	US-9782380-B2
Application number	US-201715496352-A
Country	US
Kind code	B2
Filing date	Apr 25, 2017
Priority date	Dec 3, 2015
Publication date	Oct 10, 2017
Grant date	Oct 10, 2017

Abstract

A method for treating cancer and gold(III) complexes with diaminocyclohexane ligand as anticancer agents. Also described are a pharmaceutical composition incorporating the gold(III) complexes and a method of synthesizing the gold(III) complexes.

First claim

The invention claimed is:

1. A method for treating cancer, comprising:
administering an effective amount of at least one of a gold(III) complex represented by formula (I), a gold(III) complex represented by formula (II):

a pharmaceutically acceptable salt, solvate, prodrug, or a combination thereof to a subject;
wherein the cancer is ovarian cancer, Hodgkin lymphoma, or both;
each of R 1 is independently selected from the group consisting of a hydrogen and a methyl group;
each of R 2 is independently selected from the group consisting of a hydrogen, a halogen, a hydroxyl, an amino, a nitro, a cyano, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted arylalkyl, an optionally substituted heteroaryl, an optionally substituted alkoxyl, an optionally substituted aryl, an optionally substituted alkenyl, a N-monosubstituted amino group, and a N,N-disubstituted amino group; and
X is a chloride anion.

2. The method of claim 1 , wherein R 2 is hydrogen.

3. The method of claim 1 , wherein the gold(III) complex represented by formula (I) is

and the gold(III) complex represented by formula (II) is

4. The method of claim 1 , wherein the gold(III) complex represented by formula (I) and/or the gold(III) complex represented by formula (II) is administered to the subject as the pharmaceutically acceptable salt comprising at least one counterion which is at least one pharmaceutically acceptable anion selected from the group consisting of fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, methanesulfonate, ethanesulfonate, p-toluenesulfonate, salicylate, malate, maleate, succinate, tartrate, citrate, acetate, perchlorate, trifluoromethanesulfonate, acetylacetonate, hexafluorophosphate, and hexafluoroacetylacetonate.

5. The method of claim 4 , wherein the at least one counterion is chloride.

6. The method of claim 1 , wherein the cancer is ovarian cancer, and the ovarian cancer is resistant to cisplatin.

7. The method of claim 1 , wherein the cancer is Hodgkin lymphoma and the Hodgkin lymphoma is classical Hodgkin lymphoma.

8. The method of claim 1 , further comprising measuring a concentration of a biomarker and/or detecting a mutation in the biomarker before and/or after the administering.

9. The method of claim 8 , wherein the biomarker is at least one selected from the group consisting of BRCA1, BRCA2, CCL17, CD163, CD30, NF-κB, Gal-1, CA125, HE4, mesothelin, transthyretin, ApoA1, VCAM, IL-6, IL-8, B7-H4, serum amyloid A, transferrin, osteopontin, kallikreins, OVX1, VEGF, AGR-2, inhibin, M-CSF, uPAR, EGF receptor, lysophosphatidyl acid, beta2-microglobulin, miRNA, and Epstein-Barr virus DNA.

10. The method of claim 9 , wherein the concentration of the biomarker is measured with an ELISA assay and/or the mutation in the biomarker is measured with a PCR assay.

11. The method of claim 1 , wherein the subject is a mammal.

12. The method of claim 1 , wherein the effective amount of the at least one of the gold(III) complex represented by formula (I), the gold(III) complex represented by formula (II), the pharmaceutically acceptable salt, solvate, prodrug, and a combination thereof is in a range of 1-100 mg/kg.

Assignees

• Univ King Fahd Pet & Minerals

Inventors

• Isab Anvarhusein A
• Altaf Muhammad

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57545

  of the ovaries · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• G01N33/57449

  Physics · mapped topic

• C12Q2600/156

  Polymorphic or mutational markers · CPC title